MedTrace Logo

Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study

NCT00481429 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-07-10

No results posted yet for this study

Summary

Hypothesis:

A cluster of biochemical measurements (biomarkers) predict which diabetic patients will respond to treatment with a therapeutic dose of rosiglitazone over a 12 week treatment period.

Brief Summary:

The purpose of this study is to assess the predictive value of the biomarkers in diabetic patients treated with a full dose of a thiazolidinedione (eg 4mg bid rosiglitazone) for 12 weeks.

Specifically - the questions asked are:

1. Do baseline measurements of a selected panel of biomarkers predict the patients' response to rosiglitazone over 12 weeks?
2. How does the panel of biomarkers change over that 12 week treatment period?

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Rosiglitazone

Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.

Sponsors & Collaborators

Principal Investigators

  • Martin R Wilkins, MD FRCP · Imperial College London

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00481429 on ClinicalTrials.gov